Abstract Details

Title Role of Apolipoprotein E genotype in the occurrence of atypical parkinsonian syndromes

Topic Movement Disorders

Presentation(s) Movement Disorders Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 096

Objective To investigate the effect of APOE gene on atypical parkinsonian syndromes (APS) occurrence in Tunisian population.

Background APS encompass a spectrum of neurodegenerative diseases, including multiple system atrophy (MSA), progressive supranuclear palsy (PSP), corticobasal syndrome (CBS) and dementia with Lewy bodies (DLB). The effect of the APOE gene on the risk of these diseases is controversial and understudied in several populations.

Design/Methods We performed genotyping and logistic regression analyses to examine APOE associated risk in total of 291 clinically-diagnosed APS cases (DLB (n=149), PSP (n=53), MSA (n=46), CBS (n=30) and APS of undetermined origin (n=13)), patients with Alzheimer’s disease (AD) (n=500) and Parkinson’s disease (PD) (n=251) and compared them to those from neurologically healthy controls.

Results We demonstrated that APOE ε4 carriers had a statistically significant increased risk of developing DLB (OR: 1.84, IC 95%: 1.71 à 2.63, p = 0.014), PSP (OR : 1.74, IC95% :1.69-1.86, p=0.049), CBS (OR :1.62, IC95% : 1.59-1.66, p=0.038), AD (OR: 2.31, 95% IC: 1.56-3.87, p = 0.044), and marginally among PD patients (OR: 1.66, IC 95%: 1.12 à 4.91, p = 0.080). These results surpassed the Bonferroni threshold for multiple comparisons. In contrast, carriers of the APOE ε2 allele had a marginally decreased risk of developing DLB (OR: 0.85, IC 95%: 0.01-0.39; p = 0.053) and significantly decreased risk of developing AD (OR: 0.89, 95% IC: 0.02-0.91; p = 0.018).

Conclusions This study suggests the role of APOE ε4 in the occurrence of DLB, PSP and CBD but not in MSA and the protective effect of APOE ε2 in DLB. Studies in larger neuropathologically-confirmed cohorts are needed to better establish these results.

Authors/Disclosures
Amina Nasri, MD (Department of Neurology, Razi University Hospital) PRESENTER	Dr. Nasri has nothing to disclose.
Amina Nasri, MD (Department of Neurology, Razi University Hospital)	Dr. Nasri has nothing to disclose.
Amina Nasri, MD (Department of Neurology, Razi University Hospital)	Dr. Nasri has nothing to disclose.
	No disclosure on file
	No disclosure on file
Imen Kacem, MD (Department of Neurology)	Dr. Kacem has nothing to disclose.
Riadh Gouider, MD, F�鶹��ýӳ�� (Erazi Hospital)	Dr. Gouider has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Gouider has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Gouider has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Gouider has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Gouider has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hikma. The institution of Dr. Gouider has received research support from Clinical Investigation Center. The institution of Dr. Gouider has received research support from Menactrims.

�鶹��ýӳ��

�鶹��ýӳ��